TLDR:
PTX Capital and Blackbird BioVentures join $4.5M funding round for Infinity Bio, an antibody profiling company. The company combines cutting-edge technology with a practical high-throughput approach to map antibody reactivity at scale across viral antigens, self-antigens, and allergens.
Article Summary:
Baltimore-based Infinity Bio, founded by H. Benjamin Larman and Steve Elledge, has raised $4.5 million in a funding round led by PTX Capital and Blackbird BioVentures. The company has developed new technology for antibody profiling, which can be used to uncover disease mechanisms, develop vaccines, and identify immune responses, including for various cancers.
Infinity Bio utilizes a technology called Molecular Indexing of Proteins by Self-Assembly (MIPSA) to map antibody reactivity at scale. This technology, combined with a high-throughput approach, promises to unlock insights into important human diseases by revealing how individual immune systems perceive the world.
The company, led by CEO Joy Nassif, offers a Science-as-a-Service model and aims to partner in healthcare innovation. The board includes Caroline Popper, an internist and pathologist associated with Johns Hopkins Bloomberg School of Public Health.
PTX Capital and Blackbird BioVentures, both prominent venture capital firms, have made significant investments in Infinity Bio. PTX Capital, based in Baltimore, has made six investments since its inception in 2021, while Blackbird BioVentures’ portfolio includes companies like Modra, ProFlowers, AlloCrypt, and Talapa Bio.
Overall, Infinity Bio’s funding round and innovative technology have positioned the company as a key player in antibody profiling and disease research, with potential implications for vaccines, cancer treatment, and immune response understanding.
